JP2016512828A - ラセカドトリル脂質組成物 - Google Patents

ラセカドトリル脂質組成物 Download PDF

Info

Publication number
JP2016512828A
JP2016512828A JP2016501378A JP2016501378A JP2016512828A JP 2016512828 A JP2016512828 A JP 2016512828A JP 2016501378 A JP2016501378 A JP 2016501378A JP 2016501378 A JP2016501378 A JP 2016501378A JP 2016512828 A JP2016512828 A JP 2016512828A
Authority
JP
Japan
Prior art keywords
composition
oil
racecadotril
weight
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512828A5 (enExample
Inventor
リー，ダー−ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenvue Brands LLC
Original Assignee
Johnson and Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Consumer Inc filed Critical Johnson and Johnson Consumer Inc
Publication of JP2016512828A publication Critical patent/JP2016512828A/ja
Publication of JP2016512828A5 publication Critical patent/JP2016512828A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016501378A 2013-03-15 2014-03-12 ラセカドトリル脂質組成物 Pending JP2016512828A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787597P 2013-03-15 2013-03-15
US61/787,597 2013-03-15
PCT/US2014/023903 WO2014150660A1 (en) 2013-03-15 2014-03-12 Racecadotril lipid compositions

Publications (2)

Publication Number Publication Date
JP2016512828A true JP2016512828A (ja) 2016-05-09
JP2016512828A5 JP2016512828A5 (enExample) 2017-02-09

Family

ID=50628914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501378A Pending JP2016512828A (ja) 2013-03-15 2014-03-12 ラセカドトリル脂質組成物

Country Status (15)

Country Link
US (2) US9801819B2 (enExample)
EP (1) EP2968138B1 (enExample)
JP (1) JP2016512828A (enExample)
KR (1) KR20160101167A (enExample)
CN (1) CN105246460A (enExample)
AU (2) AU2014235733B2 (enExample)
BR (1) BR112015023387A2 (enExample)
CA (2) CA2907195A1 (enExample)
IL (1) IL241065A0 (enExample)
MX (2) MX2015012345A (enExample)
PH (1) PH12015502014A1 (enExample)
RU (2) RU2662069C2 (enExample)
SA (1) SA515361092B1 (enExample)
WO (2) WO2014150660A1 (enExample)
ZA (1) ZA201507661B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6622950B1 (ja) * 2019-07-08 2019-12-18 株式会社Moresco マイクロエマルションを調製するための組成物、マイクロエマルション、これらの製造方法、及びマイクロエマルションの利用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702930A (en) 2012-06-28 2017-05-26 Mcneil Ppc Inc Racecadotril liquid compositions
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
US10039712B2 (en) 2012-06-28 2018-08-07 Johnson & Johnson Consumer Inc. Racecadotril lipid compositions
EP3086777A1 (en) * 2013-12-23 2016-11-02 Johnson & Johnson Consumer Inc. Racecadotril compositions
EP3331520A1 (en) * 2015-08-07 2018-06-13 Johnson & Johnson Consumer Inc. Methods of treatment using cadotril compositions
RU2745888C2 (ru) * 2016-08-23 2021-04-02 Джонсон энд Джонсон Консьюмер Инк. Новая улучшенная композиция рацекадотрила
EP3716954A1 (en) 2017-11-27 2020-10-07 Umecrine Cognition AB Pharmaceutical formulation of 3 -ethynyl-3 -hydroxyandrostan-17-one oxime
US20210378970A1 (en) * 2018-02-26 2021-12-09 R.P. Scherer Technologies, Llc Pharmaceutical dosage form for an emulsion of simethicone and loperamide
WO2022090490A1 (en) * 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease
WO2025212856A1 (en) * 2024-04-05 2025-10-09 The Board Of Regents Of The University Of Texas System Microemulsion formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012076691A1 (en) * 2010-12-10 2012-06-14 Bioprojet New form of administration of enkephalinase inhibitor
JP2015522031A (ja) * 2012-06-28 2015-08-03 マクニール−ピーピーシー・インコーポレーテツド ラセカドトリル脂質組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
FR2623498B1 (fr) 1987-11-24 1990-04-06 Bioprojet Soc Civ Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques
US5136076A (en) 1987-11-24 1992-08-04 Societe Civile Bioprojet Process for the preparation of amino acid-derived enatiomeric compounds
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
US20020028248A1 (en) 1996-03-14 2002-03-07 Takayuki Tsukada Rapid-release microdispersible ecadotril preparation
WO1998040051A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
GB0015490D0 (en) 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
ES2247163T3 (es) 2000-06-23 2006-03-01 Bioprojet Formulacion en polvo seca que comprende racedotril.
EP1563848A1 (en) 2004-02-12 2005-08-17 Bioprojet New combinations of an anti-emetic agent and an enkephalinase inhibitor
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
CN101103960B (zh) 2006-07-14 2010-12-08 海南盛科生命科学研究院 一种含有消旋卡多曲的干混悬剂及其制备方法
CN101264065A (zh) 2008-04-18 2008-09-17 盐城苏海制药有限公司 消旋卡多曲滴丸及其制备方法
WO2011002702A1 (en) 2009-06-29 2011-01-06 Mcneil-Ppc, Inc. Pharmaceutical tablet containing a liquid filled capsule
CN102018707A (zh) * 2010-11-29 2011-04-20 昆明邦宇制药有限公司 一种治疗腹泻的药物组合物及其制剂
CN102133186B (zh) 2011-03-18 2012-08-01 海南美大制药有限公司 一种消旋卡多曲脂质体固体制剂
CN102327234B (zh) 2011-09-28 2017-04-12 海南康芝药业股份有限公司 一种消旋卡多曲干混悬剂
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
NZ702930A (en) 2012-06-28 2017-05-26 Mcneil Ppc Inc Racecadotril liquid compositions
US9114171B2 (en) 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
EP2749270B1 (en) 2012-12-26 2018-01-17 ILKO Ilaç Sanayi ve Ticaret A.S. Racecadotril and pharmaceutical compositions thereof
EP3331520A1 (en) 2015-08-07 2018-06-13 Johnson & Johnson Consumer Inc. Methods of treatment using cadotril compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012076691A1 (en) * 2010-12-10 2012-06-14 Bioprojet New form of administration of enkephalinase inhibitor
JP2015522031A (ja) * 2012-06-28 2015-08-03 マクニール−ピーピーシー・インコーポレーテツド ラセカドトリル脂質組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
薬剤学, vol. 70, no. 1, JPN6017006914, 2010, pages 32 - 38, ISSN: 0003810783 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6622950B1 (ja) * 2019-07-08 2019-12-18 株式会社Moresco マイクロエマルションを調製するための組成物、マイクロエマルション、これらの製造方法、及びマイクロエマルションの利用
WO2021005676A1 (ja) * 2019-07-08 2021-01-14 株式会社Moresco マイクロエマルションを調製するための組成物、マイクロエマルション、これらの製造方法、及びマイクロエマルションの利用

Also Published As

Publication number Publication date
WO2015100234A1 (en) 2015-07-02
RU2662069C2 (ru) 2018-07-23
US20140271832A1 (en) 2014-09-18
CA2907195A1 (en) 2014-09-25
IL241065A0 (en) 2015-11-30
MX2016008390A (es) 2017-01-11
US20140275246A1 (en) 2014-09-18
MX2015012345A (es) 2017-03-27
RU2015144013A (ru) 2017-04-28
BR112015023387A2 (pt) 2017-07-18
WO2014150660A1 (en) 2014-09-25
PH12015502014A1 (en) 2016-01-11
RU2016129907A (ru) 2018-01-30
AU2014235733A1 (en) 2015-09-24
SA515361092B1 (ar) 2018-01-17
RU2016129907A3 (enExample) 2018-09-13
AU2014370027A1 (en) 2016-07-07
US9801819B2 (en) 2017-10-31
EP2968138B1 (en) 2018-08-15
EP2968138A1 (en) 2016-01-20
CN105246460A (zh) 2016-01-13
ZA201507661B (en) 2017-09-27
US20160331684A9 (en) 2016-11-17
CA2934816A1 (en) 2015-07-02
US9636300B2 (en) 2017-05-02
KR20160101167A (ko) 2016-08-24
AU2014235733B2 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
JP6282645B2 (ja) ラセカドトリル脂質組成物
US9636300B2 (en) Racecadotril lipid compositions
CN100367951C (zh) 丁苯酞静脉乳剂及其应用
JP2016106152A (ja) 生物学的利用能を向上した医薬組成物
KR20010093281A (ko) 자발분산성 ｎ-벤조일-스타우로스포린 조성물
JP2012180337A (ja) 自己乳化製剤
RU2639482C2 (ru) Фармацевтические композиции
JP5036114B2 (ja) テルビナフィン含有医薬組成物
JP2017500355A (ja) ラセカドトリル組成物
KR20020042218A (ko) 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용약제 조성물
HK1208178B (en) Racecadotril lipid compositions
KR20050011323A (ko) 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용약제 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180605